Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astellas Pharma Inc (ALPMF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.1320 unch
on 04/17/19
15.6400 -9.64%
on 03/26/19
-1.0180 (-6.72%)
since 03/11/19
3-Month
14.0200 +0.80%
on 01/24/19
15.6400 -9.64%
on 03/26/19
+0.2819 (+2.04%)
since 01/15/19
52-Week
12.7600 +10.75%
on 12/31/18
17.7600 -20.43%
on 09/26/18
-0.6680 (-4.51%)
since 04/17/18

Most Recent Stories

More News
Ragweed Pollen Allergy Pipeline Review, H1 2019 Featuring ALK-Abello, Allergy Therapeutics, Anergis, Astellas Pharma, & Biomay - ResearchAndMarkets.com

The "Ragweed Pollen Allergy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

ALPMF : 14.1320 (-1.79%)
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

-- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates --

ALPMF : 14.1320 (-1.79%)
XNCR : 31.83 (-2.39%)
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations

Vancouver, British Columbia--(Newsfile Corp. - April 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions...

ALPMF : 14.1320 (-1.79%)
NGEN.VN : 1.560 (-2.50%)
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA® (gilteritinib) to salvage chemotherapy...

ALPMF : 14.1320 (-1.79%)
Nocturia - Pipeline Insight Report, 2019 Featuring Allergan, Astellas Pharma, Ferring International Center, Sanwa Kagaku Kenkyusho Co, and Vantia Therapeutics - ResearchAndMarkets.com

The "Nocturia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

AGN : 139.66 (-1.77%)
ALPMF : 14.1320 (-1.79%)
Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract...

ALPMF : 14.1320 (-1.79%)
NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides

NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary oligonucleotide delivery technology to develop novel agents, today announced that the company has entered into a research collaboration...

ALPMF : 14.1320 (-1.79%)
Global Aspergillosis Drugs Market Report 2019-2023 with Market Positioning of Key Vendors - Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer

The "Global Aspergillosis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

MRK : 74.73 (+0.17%)
ALPMF : 14.1320 (-1.79%)
Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas

--Initiation of clinical study triggers milestone payment to Affinivax

ALPMF : 14.1320 (-1.79%)
Astellas Pharma Canada, Inc. named to the 2019 List of Best Workplaces(TM) for Inclusion

Astellas Pharma Canada, Inc. is proud to announce that the Company has been named on the 2019 list of Best WorkplacesTM for Inclusion. Astellas received this recognition after a thorough and independent...

ALPMF : 14.1320 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ALPMF with:

Key Turning Points

2nd Resistance Point 14.1320
1st Resistance Point 14.1320
Last Price 14.1320
1st Support Level 14.1320
2nd Support Level 14.1320

See More

52-Week High 17.7600
Fibonacci 61.8% 15.8500
Fibonacci 50% 15.2600
Fibonacci 38.2% 14.6700
Last Price 14.1320
52-Week Low 12.7600

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar